Elekta stock faces heightened short interest as insider buying meets hedge-fund pressure

Published on 09/18/2026 at 19:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Elekta stock traded around SEK 51.40 on Nasdaq Stockholm on September 17, 2026, as insider share purchases signaled management confidence. At the same time, a new 0.52 percent public short position by Brummer Multi-Strategy adds to a total 15.19 percent of Elekta’s capital sold short.

Flatlay mit Aktienzertifikat, ISIN-Karte und medizinischen Utensilien auf weißem Untergrund — Flatlay-Arrangement mit Aktienzertifikat und ISIN-Karte SE0000163628 zeigt Investment-Utensilien passend zur Branche von Elekta AB, Illustration mit AI erstellt.

Elekta AB stock (ISIN SE0000163628) closed at SEK 51.40 on Nasdaq Stockholm on September 17, 2026, down 0.58 percent from the prior session, putting the medical technology group in the spotlight as insider buying and rising short interest converge around the share price ahead of September 18, 2026.

Insider buying at SEK 51.40 supports Elekta stock

According to Placera, Elekta B shares last traded at SEK 51.40, with a one day performance of negative 0.68 percent in the latest trading overview dated September 18, 2026, confirming that the stock is hovering just above the SEK 50 mark.

Earlier, as a Swedish market brief relayed on September 18, 2026, Elekta’s chief financial officer Klara Eiritz bought 3,655 Elekta B shares on September 17, 2026 at a price of SEK 51.40 per share, a transaction of almost SEK 0.2 million that underpins management’s confidence in the current valuation.

Hedge fund short build-up raises risk for Elekta stock

As MarketScreener reported on September 18, 2026, hedge fund Brummer Multi-Strategy has taken a new public short position in Elekta equal to 0.52 percent of the share capital, after previously staying just below the 0.5 percent disclosure threshold.

According to the same MarketScreener note, there are now eleven public short sellers in Elekta and, in aggregate, 15.19 percent of the company’s share capital is sold short, a level that indicates substantial bearish positioning and raises the potential for volatility if sentiment or fundamentals shift.

Valuation context and recent insider accumulation

Additional context comes from Simply Wall St, which highlighted on September 18, 2026 that Elekta’s CEO and president Jakob Just-Bomholt recently bought approximately SEK 9.9 million worth of Elekta shares at a price of SEK 49.49 per share, representing an increase of about 20 percent in his personal holding.

The same Simply Wall St analysis describes Elekta as a medical technology company providing clinical solutions for treating cancer and brain disorders across the Americas, Europe, the Middle East, Africa and Asia Pacific, and characterizes the stock as undervalued with high growth potential while noting that it pays a dividend, offering investors both growth and income exposure in the healthcare equipment space.

Price level and market data for Elekta stock

Per the latest Swedish trading overview referenced by Placera on September 18, 2026, Elekta B last changed hands at around SEK 51.40 on Nasdaq Stockholm, implying that the CEO’s recent purchase at SEK 49.49 was made at a roughly 3.9 percent discount to the latest level, while the chief financial officer’s trade at SEK 51.40 matched the prevailing market price.

An overview on Dagens Industri lists Elekta B under the EKTA B ticker on Nasdaq Stockholm’s Large Cap segment with 383,568,409 shares outstanding, confirming the company’s classification in the healthcare sector and providing a basis for market capitalization calculations at current price levels.

Elekta stock and investor perspective

With insider purchases by both the CEO and CFO in recent weeks and a visible build-up of short interest led by Brummer Multi-Strategy, Elekta stock is caught between internal confidence and external skepticism, leaving investors to weigh the company’s long-term prospects, dividend profile and cancer-treatment technology pipeline against the risk implied by 15.19 percent of the capital being sold short as of September 18, 2026.